Open access
Oct 2026
Maftivimab monotherapy is effective in a non-human primate model of Bundibugyo virus disease
The 2026 outbreak of Bundibugyo ebolavirus (BDBV) in the Democratic Republic of the Congo and Uganda has created an urgent need for treatments for BDBV disease, yet the only FDA-approved ebolavirus therapeutics, the monoclonal antibody (mAb) cocktail Inmazeb® and the mAb Ebanga®, are indicated for Zaire ebolavirus (EBO...
Meike Dittmann, Dylan M. Johnson, M. Rapp et al.
· bioRxiv · 0 citations